MAP2K7 and melanoma: BRAF-mutant melanoma patients, who were previously treated with a BRAF inhibitor (with or without the addition of a MEK inhibitor) and received the PD-1 ICI not as first line therapy, had a longer survival compared to patients with a BRAF mutation and no previous BRAF inhibitor treatment (mPFS was 61 weeks vs. 12 weeks, p = 0.022) (Table 4).